Skip to main content
TipRanks
Go Ultimate75% OFF

Scancell Holdings (SCNLF) Stock Price & Analysis

19 Followers

SCNLF Stock Chart & Stats

$1.04$0.00(0.00%)
At close: 4:00 PM EST
$1.1$1.2$1.3$1.4Aug 21Sep 8Sep 9Oct 28Nov 4Nov 17
Day’s Range
$1.02 - $1.06
52-Week Range
$1.02 - $3.35
Previous Close
$1.04
Volume
N/A
Average Volume (3M)
169
Market Cap
$126.89M
Enterprise Value
$209.19M
Total Cash (Recent Filing)
$5.32M
Total Debt (Recent Filing)
$17.08M
Price to Earnings (P/E)
―
Beta
0.50
Next Earnings
Feb 04, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

FDA-cleared Phase III Pathway

FDA clearance validates the planned Phase III design, manufacturing package, endpoints, and statistical approach, materially reducing regulatory execution uncertainty. The surrogate endpoint could support an accelerated approval route, creating a clearer development and commercialization pathway if efficacy is confirmed.

Encouraging Clinical Signal

The Phase II signal provides meaningful evidence that iSCIB1+ may improve outcomes when added to established therapy, supporting further investment in the program. A biomarker identified for Phase III may also enrich responders and improve the efficiency of confirmatory development.

Platform And Partnered Pipeline

Scancell is developing multiple immunotherapy approaches rather than relying on a single candidate, while partnered antibodies provide additional potential milestones and royalties. Long patent protection, scalable manufacturing, and needle-free delivery support future commercial durability if clinical programs succeed.

Bears Say

Negative Equity And Asset Deterioration

Negative equity and a sharply reduced asset base indicate limited balance-sheet resilience relative to the company’s development obligations. With debt still about £17.1m, Scancell has less financial flexibility to absorb setbacks or fund strategic programs without additional external capital.

Persistent Cash Burn And Funding Need

Recurring operating and free-cash-flow outflows show that the business currently consumes capital rather than funding development internally. Continued burn increases dependence on financing, partnering, or milestone receipts, creating execution risk around sustaining operations and advancing the pipeline.

Long Path To Definitive Data

A blinded Phase III timeline extending to H2 2029 delays definitive confirmation of clinical benefit and potential product revenue. The extended development period requires Scancell to maintain funding for several years while efficacy updates remain limited, increasing financing and execution exposure.

Scancell Holdings News

SCNLF FAQ

What was Scancell Holdings’s price range in the past 12 months?
Scancell Holdings lowest stock price was $1.02 and its highest was $3.35 in the past 12 months.
What is Scancell Holdings’s market cap?
Scancell Holdings’s market cap is $126.89M.
When is Scancell Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Scancell Holdings overvalued?
According to Wall Street analysts Scancell Holdings’s price is currently Undervalued.
Does Scancell Holdings pay dividends?
Scancell Holdings does not currently pay dividends.
What is Scancell Holdings’s EPS estimate?
Scancell Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings have?
Scancell Holdings has 121,223,070 shares outstanding.
Which hedge fund is a major shareholder of Scancell Holdings?
Currently, no hedge funds are holding shares in SCNLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology